

Society for Clinical Data Management (SCDM) eSource Implementation Consortium

2019 Face to Face Meeting

14 October 2019 Peapack, NJ





8:00 AM-8:10 AM: Welcome/Goal of the Meeting: Linda King, Astellas Pharma, SCDM Chair

8:10-8:20 **Kick-Off: Demetris Zambas**, Pfizer Inc., Global Head Data Monitoring and Management

8:20-8:30 Introductions, Roles, Expectations: Mike Buckley, MSKCC, <u>SCDM eSource</u> Implementation Co-Chair

8:30-9:00 Read out of HL7 9/15 eSource Thought Leader Meeting, Rakesh Maniar, Novartis, Inc., TransCelerate BioPharma, Inc. (TCB), eSource Initiative Co-Lead, SCDM eSource Implementation Co-Chair

9:00-9:30 Where Do We Fit? Review of Current and Planned Deliverables for TCB, Biomedical Research and Regulation Working Group (BR&R), Health Level Seven International (HL7), and SCDM

TCB Perspective: Rakesh Maniar

SCDM eSource Perspective: Mike Buckley

BR&R Perspective: Amy Nordo, Pfizer Inc, HC7 Clinical Interoperability Council (CIC)

Co-Chair

9:30-10:00 Break and Group Picture

10:00-11:00 2019 Three Tracks Review: Linda King

State 1A: eLabs White paper, Hugh Dai, Eli Lilly, Inc.

State 1B: Tech workstream: FHIR + MSKCC + Pfizer Amy Nordo, Pfizer, Inc., HL7 CIC

Co-Chair

State 2: Future State Leveraging HL-7 BR&R Implementation Guide: All

11:00-12:00 2020 Road Map, Wrap Up and Action Items, Rakesh Maniar

12:00-1:00 Lunch

Welcome!!!

Current Steering Committee Membership Roster



Sponsors

Technology Vendors

Novartis

Advarra Forte

Merck

Eli Lilly

Bristol Myers Squibb

Pfizer

Sites

MSKCC

Yale School of Medicine

Duke University School of Medicine

Washington University- St. Louis, School of Medicine

University of Manchester, UK (under discussion)

Standards Development
Organizations

HL7

CDISC (under discussion)

SCDM © 2019

Welcome and Goal of Our Meeting



Linda King, SCDM Chair, Board Liaison to Consortium (Astellas Pharma)

Consortium Vision

Leading biopharmaceutical companies, academic medical centers, and healthcare technology providers have partnered to create an eSource Implementation Consortium (Consortium) with the vision of enabling a faster and more efficient digital exchange of clinical research source data from academic medical sites to industry sponsors, through Electronic Health Records (EHR) to Electronic Data Capture (EDC) and Clinical Data Management Systems (CDMS). The Consortium seeks to streamline existing data transfer processes to free up site staff to focus on patient touchpoints.

Welcome and Goal of Our Meeting



Linda King, SCDM Chair, Board Liaison to Consortium (Astellas Pharma)

Consortium Mission

The mission of this academic-industry eSource Implementation Consortium is to agree upon standardization of clinical research data sets that will enable faster adoption of direct data transfers by academic sites and industry sponsors. We will implement this mission by leveraging existing clinical research HL7 Fast Healthcare Interoperability Resources (FHIR) standards where available.

Welcome and Goal of Our Meeting

Linda King, SCDM Chair, Board Liaison to Consortium (Astellas Pharma)



Scope of SCDM

- New vision and mission for the Society
- Expanded SCDM scope from clinical data management to clinical data science
- Key objectives of SCDM: Education, Thought leadership and Advocacy
- Increased engagement with other Societies and associations; A Connector
- eSource Implementation Consortium fits well with our expanded scope, vision and mission

Our Vision: "Leading innovative clinical data science to advance global health research and

development"

Our Mission: "Connect and inspire professionals managing global health data with global education, certification and advocacy"

Today's Goals



- Review current landscape and align on Consortium's opportunity
- Energize and continue to execute on leveraging our 2019 roadmap tracks using HL7 FHIR® for acquisition, exchange, and use of data for clinical research
- Plan our 2020 roadmap (what/who/how)

Kick-Off

Demetris Zambas

Pfizer Inc., Global Head Data Monitoring and Mgmt.



Introductions, Roles, Expectations



Mike Buckley

MSKCC, SCDM eSource Implementation Co-Chair

- <u>Steering Committee</u>: decision makers for our roadmap and deliverables (appoint deputy decision makers)
- Harmonize across Sites, Industry and Technology Vendors
- Recruitment champions → membership
- 2019 Deliverables update
- 2020 Planning and Succession (Vice Chairs)

eSource Implementation Consortium 2019 Workstreams LOCAL LABS LOCAL LABS LOCAL LABS State IA State IB State II Flat File Xfers. **Future State** FHIR Exchange HL7-BR&R Team Lead: H. Dai Feam Lead: M. Koch/Amy • Q1: use in dev. Q2-Q3: POC Q2:Analysis phase · Q2: use in production Q3-Q4: use in prod. Q3: use in dev. Guide: Q3-Q4 Q4: use in production Implementation Implementation Guide or Best Guide, Best Practices Practices paper Use in production Lilly: H. Dai MSK: M. Koch MSK: M. Buckley NVS: A Vattikola + DM and IT staff Pfizer: A. Nordo M. Cherry · Lilly: Hugh Dai FHIR experience Use of flat file xfers. Standards creation · Desire and resources Know how a restful. to implement API works Desire and resources

SCDM © 2019

Read out of HL7 9/15 eSource Thought Leader Meeting



Rakesh Maniar,

Novartis, Inc., TransCelerate BioPharma, Inc. (TCB), eSource Initiative Co-Lead, SCDM eSource Implementation Co-Chair

Amy Nordo, MMCi, BSN CPHQ, HL7 CIC Co-Chair Pfizer, Inc.



Reflections from attendees
Shannon Roznoski
Aruna Vattikola
Mike Buckley



Where Do We Fit? Review of Current and Planned Deliverables



TransCelerate Biopharma (TCB): Rakesh Maniar

SCDM eSource Implementation Consortium: Mike Buckley

Biomedical Research and Regulation (BR&R) Working Group: Amy Nordo

TCB Perspective



Rakesh Maniar, Novartis, Inc., TCB eSource Initiative Co-Lead, SCDM eSource Implementation Co-Chair





Current Work Streams with HL7 FHIR®

WORKSTREAM 1 MSK Sponsor/CRO Authenticated data request Pfizer FHIR® Data Extract **Lab Information FHIR® Institutional Data Local Labs** System (LIS) Server Genentech Warehouse Secure data retrieval **WORKSTREAM 2** Vendor discussions for two sponsored protocols

BR&R Perspective



Amy Nordo

Pfizer Inc.

HL7 Clinical Interoperability Council (CIC) Co-Chair

- Lab Implementation Guide
- Adverse Event Reporting
- FHIR to BRIDG



Break and Group Picture





2019 Three Tracks Review

Linda King, SCDM Chair, Board Liaison, Astellas Pharma

eSource Implementation Consortium 2019 Workstreams

esource implementation Consortium 2019 Workstreams					
WORKSTREAM	LOCAL LABS State IA Flat File Xfers.	LOCAL LABS State IB FHIR Exchange	LOCAL LABS State II Future State HL7-BR&R		
TEAM LEAD & DUE DATE	Team Lead: H. Dai Q1: use in dev. Q2: use in production Paper: Q2	Team Lead: M. Koch/Amy Nordo Q2-Q3: POC Q3-Q4: use in prod. Guide: Q3-Q4	 Q2:Analysis phase Q3: use in dev. Q4: use in production 		
DELIVERABLE	Implementation Guide or Best Practices paper Use in production	Implementation Guide, Best Practices paper			
eSOURCE MEMBERS	Lilly: H. Dai MSK: M. Buckley NVS: R. Maniar	MSK: M. Koch NVS: A. Vattikola + DM and IT staff Pfizer: A. Nordo, M. Cherry Lilly: Hugh Dai			
KNOWLEDGE REQUIREMENTS	 Use of flat file xfers. Desire and resources to implement 	FHIR experience Standards creation Know how a restful API works Desire and resources to implement			

State 1A: eLabs White paper

Hugh Dai, Eli Lilly, Inc.





Local Lab Solution

October 14, 2019






Objectives

- "Think Big, Start Small, Learn Fast"
- Share experiences and outcomes
- Privacy and security considerations
- Flat file transfer Pro/Con
- Sample technology and template


SCDM © 2019

© 2016 Eli Lilly and Company Transformation



© 2016 Eli Lilly and Company


eCRF local lab collection example



Available: Well-formatted data source

```
SiteID|SubjectID|SiteName|ResultDate|ResultTime|TestCode|TestName|Result|Unit|LowerLimit|UpperLimit|
001|1002 (---)|Memorial Sloan Kettering Cancer Center|3-Jun-15|9:17|15060303671 UBLD|Blood|NEGATIVE||||
001|1002 (---) | Memorial Sloan Kettering Cancer Center|3-Jun-15|9:17|15060303671 UGLUC|Glucose|NEGATIVE|mg/dl|||
001|1002 (---) | Memorial Sloan Kettering Cancer Center|3-Jun-15|9:17|15060303671 UKET|Ketone|NEGATIVE|mg/dl|||
001|1002 (---)|Memorial Sloan Kettering Cancer Center|3-Jun-15|9:17|15060303671 LEU|Leukocyte Esterase|SMALL||||
001|1002 (---)|Memorial Sloan Kettering Cancer Center|3-Jun-15|9:17|15060303671 UALB|Protein|NEGATIVE|mg/dl|||
001|1002 (---) | Memorial Sloan Kettering Cancer Center|3-Jun-15|9:17|15060303671 USPG | Specific Gravity | 1.016||1.003|1.03|
001|1002 (---)|Memorial Sloan Kettering Cancer Center|3-Jun-15|9:17|15060303671 UPH|pH|5.5||4.6|7|
001|1002 (---)|Memorial Sloan Kettering Cancer Center|3-Jun-15|9:17|15060303662 ABAS|Absolute Basophil|0.1|K/mcL|0|0.2|
001|1002 (---)|Memorial Sloan Kettering Cancer Center|3-Jun-15|9:17|15060303662 AEOS|Absolute Eosinophil|0.2|K/mcL|0|0.8|
001|1002 (---) | Memorial Sloan Kettering Cancer Center|3-Jun-15|9:17|15060303662 ALYM|Absolute Lymphocyte|0.7|K/mcL|0.5|5.3|
001|1002 (---)|Memorial Sloan Kettering Cancer Center|3-Jun-15|9:17|15060303662 AMON|Absolute Monocyte|0.4|K/mcL|0|1.3|
001|1002 (---) | Memorial Sloan Kettering Cancer Center|3-Jun-15|9:17|15060303662 ANEUT|Absolute Neutrophil|4.7|K/mcL|1.5|8.8|
001|1002 (---) | Memorial Sloan Kettering Cancer Center|3-Jun-15|9:17|15060303662 HCT|Hematocrit|34.5|%|34|46|
001|1002 (---)|Memorial Sloan Kettering Cancer Center|3-Jun-15|9:17|15060303662 HGB|Hemoglobin|10.5|g/dL|11.5|16|
001|1002 (---)|Memorial Sloan Kettering Cancer Center|3-Jun-15|9:17|15060303662 MCV|Mean CORPUSCULAR Volume|82|fL|82|98
001|1002 (---) | Memorial Sloan Kettering Cancer Center|3-Jun-15|9:17|15060303662 MCH|Mean Corpuscular Hemoglobin|24.8|pg|27|33
001|1002 (---) | Memorial Sloan Kettering Cancer Center|3-Jun-15|9:17|15060303662 MCHC|Mean Corpuscular Hemoglobin Concentration|30.4|g/dL|31|36.5|
001|1002 (---)|Memorial Sloan Kettering Cancer Center|3-Jun-15|9:17|15060303662 UNVPLT|Platelets|186|K/mcL|160|400|
001|1002 (---) | Memorial Sloan Kettering Cancer Center|3-Jun-15|9:17|15060303662 RBC|Red Blood Cell|4.23|M/mcL|4|5.2|
001|1002 (---)|Memorial Sloan Kettering Cancer Center|3-Jun-15|9:17|15060303662 RCDW|Red Cell Distribution Width|16.5|%|11.5|14.5|
001|1002 (---)|Memorial Sloan Kettering Cancer Center|3-Jun-15|9:17|15060303662 WBC|WBC|6|K/mcL|4|11|
001|1002 (---)|Memorial Sloan Kettering Cancer Center|3-Jun-15|9:17|15060303663 PALT|Alanine Aminotransferase (ALT), Plasma|7|U/L|5|37|
001|1002 (---) | Memorial Sloan Kettering Cancer Center|3-Jun-15|9:17|15060303663 PALB|Albumin, Plasma|3.9|g/dL|4|5.2|
001|1002 (---)|Memorial Sloan Kettering Cancer Center|3-Jun-15|9:17|15060303663 PALK|Alkaline Phosphatase (ALK), Plasma|77|U/L|45|129|
001|1002 (---) | Memorial Sloan Kettering Cancer Center|3-Jun-15|9:17|15060303663 PGOT|Aspartate Aminotransferase (AST), Plasma|32|U/L|10|37|
001|1002 (---)|Memorial Sloan Kettering Cancer Center|3-Jun-15|9:17|15060303663 PBUN|Blood Urea Nitrogen, Plasma|10|mg/dL|6|20|
001|1002 (---) | Memorial Sloan Kettering Cancer Center|3-Jun-15|9:17|15060303663 PLCA|Calcium, Plasma|10|mg/dL|8.5|10.5|
001|1002 (---) | Memorial Sloan Kettering Cancer Center|3-Jun-15|9:17|15060303663 PLCL|Chloride, Plasma|98|mEg/L|98|109|
001|1002 (---)|Memorial Sloan Kettering Cancer Center|3-Jun-15|9:17|15060303663 PLC02|C02, Plasma|31|mEq/L|24|30
```

Data Flow




PoC Methodology

- 1. Two sites, seven perspective oncology studies
- 2. Parallel data collections (EDC and eLab)
- 3. Data collection: 6/20/17-8/18/17
- 4. 2,546 lab results from 6 studies / 26 patients

Objectives	Baseline	Goal
Connect site clinical data directly	None exist	Enable
Data availability post-visit	~25 day	< 7 days
Accuracy (data entry error)	~8%	Near 0%

24

PoC Outcomes



© 2016 Eli Lilly and Company

eLab Whitepaper (Draft)

SCDM eSource Implementation Consortium.

Direct Data Extraction and Exchange of Local Labs for Clinical Research Protocols: A Partnership with Academic Medical Centers, Biopharmaceutical Companies, and Clinical Research Organizations

Introduction

Traditional industry-sponsored clinical trial data entry into Electronic Data Capture (EDC) systems, and on-site sponsor source data verification from the Electronic Health Record (EHR) is inefficient, consumes valuable site and sponsor time and effort (T/E), and can introduce errors into the dataset from manual transcription processes. To address these shortcomings, both the sponsors and trial sites have been looking for alternative venues to leverage the rich EHR data. For example Memorial Sloan Kettering Cancer Center (MSKCC) launched its eTrials Program in 2014. In coordination with major biopharmaceutical sponsors, the primary goals of the program were to avoid redundancies, reduce errors, and decrease T/E for all parties involved.

The direct data extraction (DDE) and transfer process was developed to comply with the electronic source data regulatory framework of the US Food and Drug Administration (FDA),¹ the Medicines and Healthcare Products Regulatory Agency (MHRA) GXP data integrity guide,² HIPAA, and other applicable local and state laws.

This document summarizes the collective experience of the members of the Society for Clinical Data Management eSource Implementation Consortium (SCDMeSIC), whose goal is to develop Data Exchange Specifications for core safety domains and various therapeutic areas efficacy



State 1B: Tech workstream:

FHIR + MSKCC + Pfizer

Amy Nordo, Pfizer, Inc., HL7 CIC Co-Chair



State 2: Future State Leveraging HL-7 BR&R Implementation Guide: All




2020 Road Map Wrap Up Action Items



Rakesh Maniar, Novartis, Inc., TCB eSource Initiative Co-Lead, SCDM eSource Implementation Co-Chair



Team Structure (Proposed)



2020 Planning

- Identification of Consortium Vice-Chairs (Succession Planning for Mike B and Rakesh M)
- Enrollment Drive (Academia, Pharma, Regulators, CRO, Technology Vendors)
- Identification of Team Leads
- Identification of member resources to support various tracks
- Identification of conferences to present /represent
- Memorandum of Understanding HL7 Accelerator, TransCelerate, CDISC, IMI, other
- HL7 Accelerator Board Member AND/or SC?
- Priority Domains Mapping & POC in consultation with HL7 Accelerator
- Deliverables Publication Track 1A timing??
- Budget SCDM ?

Lunch

